2008
DOI: 10.1530/eje-07-0488
|View full text |Cite
|
Sign up to set email alerts
|

Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal

Abstract: Objective: It is still unknown whether prolonged treatment with somatostatin analogs (SSTa) may cause a long-lasting disease remission in GH-secreting adenomas after drug discontinuation. The aim of the present study was to investigate the evolution of GH/IGF-I secretion and tumor mass after SSTa withdrawal in patients affected by acromegaly. Patients and Design: A total of 27 patients with acromegaly (12 de novo and 15 previously operated) were treated with SSTa for a median period of 48 months and considered… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
40
3

Year Published

2009
2009
2022
2022

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 47 publications
(45 citation statements)
references
References 31 publications
2
40
3
Order By: Relevance
“…Recently, Ronchi et al (18) attempted SA suspension in 27 patients with acromegaly who had been successfully treated with octreotide or lanreotide for several years. In this multicenter study, only nine of the 27 patients (33.3%) were able to sustain a long-term remission after SA withdrawal (18).…”
Section: Discussionmentioning
confidence: 99%
“…Recently, Ronchi et al (18) attempted SA suspension in 27 patients with acromegaly who had been successfully treated with octreotide or lanreotide for several years. In this multicenter study, only nine of the 27 patients (33.3%) were able to sustain a long-term remission after SA withdrawal (18).…”
Section: Discussionmentioning
confidence: 99%
“…If IGF-I levels remain normal with this regimen, drug withdrawal may be considered in rare cases of persistent optimum control despite progressive dose reduction (DR), but lifelong monitoring of IGF-I levels should be maintained in these patients (SR). [68][69][70][71] Novel agents New pharmacological approaches to the treatment of acromegaly in advanced stages of clinical development include new SRLs with different somatostatin receptor binding profiles (such as pasireotide) 72 and oral octreotide, which uses a transient permeability enhancer to enable gut absorption. 30 Novel therapeutic approaches in early stages of clinical development include an antisense oligonucleotide of 20 bases that binds to the GH receptor mRNA and inhibits translation of the receptor protein, and a targeted secretion inhibitor, comprising a botulinum toxin-GH-releasing hormone (GHRH) chimera molecule that binds to cells expressing GHRH receptors, internalizes botulinum toxin and inhibits GH secretion.…”
Section: First-line Treatment Post-surgerymentioning
confidence: 99%
“…These treatments usually control the disease effectively, and normalising levels of GH and insulin-like growth factor 1 (IGF1) should reduce the excess morbidity and mortality associated with acromegaly (4,7,8). However, recent studies have shown that there was a relatively low percent of patients with acromegaly who might be cured after withdrawal of somatostatin analogues (up to 20%) (9,10). This means that these treatments should be monitored regularly on a lifelong basis, and as a consequence, that acromegaly has become a chronic disease requiring regular follow-up.…”
Section: Introductionmentioning
confidence: 99%